AKT2 and breast carcinoma: Investigations of ER positive human breast cancer probes revealed AKT1 deletions in 4.8%, AKT1 amplifications in 1%, AKT2 deletions in 21.1%, interestingly no AKT2 amplifications, no deletions of AKT3, but AKT3 amplifications in 9.9% of investigated ER-positive human breast cancers [200].